The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.
|Articles|September 24, 2020
EMA and FDA Accept UCB’s Marketing Applications for Bimekizumab
Author(s)BioPharm International Editors
FDA and EMA have accepted the biologics license application and marketing authorization application, respectively, for bimekizumab.
Advertisement
Global biopharmaceutical company, UCB, has announced that the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the biologics license application (BLA) and marketing authorization application (MAA), respectively, for bimekizumab.
In a Sept. 22, 2020 press release, the company revealed that the application submissions have been accepted for the investigational humanized monoclonal IgG1 antibody, bimekizumab, to be used as a treatment for adults with moderate to severe plaque psoriasis. The applications were based on data from a global Phase III clinical development program.
“After a series of positive Phase III data readouts, we are delighted to announce that the US FDA and EMA have accepted our applications to file bimekizumab as a potential new treatment for psoriasis,” said Emmanuel Caeymaex, executive vice-president Immunology Solutions and head of US, UCB, in the press release. “This milestone brings us one step closer to being able to offer a meaningful new treatment option for people living with this debilitating disease. UCB is committed to providing innovative solutions for people living with serious inflammatory diseases like psoriasis.”
Evaluation of the safety and efficacy of bimekizumab are still ongoing and the drug is not yet approved by any regulatory authority worldwide. The drug is also under evaluation for potential indications in psoriatic arthritis.
Source:
Advertisement
Related to this article
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
4
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
5